Three Sheets to Tofa

Tofacitinib has emerged as a cost-effective, off-label treatment option for refractory dermatologic conditions, though its safety profile requires nuanced clinical judgment. Data from the Oral Surveillance trial in rheumatoid arthritis patients indicates elevated risks for major adverse cardiovascular events (MACE), malignancy, and infections, particularly at 10mg twice-daily dosing in high-risk populations. While these findings necessitate rigorous patient counseling and baseline screening for cardiovascular factors and infections, the lack of comparative data between JAK inhibitors complicates direct safety assessments. Clinicians should prioritize lower doses and reserve the medication for patients lacking FDA-approved alternatives, while maintaining consistent monitoring for laboratory abnormalities. Despite theoretical concerns regarding pan-JAK selectivity, clinical efficacy appears dose-dependent rather than agent-specific. Utilizing affordable pharmacy services like Cost Plus can improve patient access for those suffering from severe, otherwise unmanageable inflammatory skin diseases.